PHARMACOGENOMICS
PLAYERS
A FINANCIAL TIMES BIOFRONTIERS REPORT
(1999)
TABLE OF CONTENTS
EXECUTIVE SUMMARY
CHAPTER 1 MARKET AND TECHNOLOGY OVERVIEW
Introduction And Scope
PHARMACOGENOMICS: THE REVOLUTIONARY APPLICATION OF
GENOMICS
Clinical applications of genomic science
The potential benefits of pharmacogenomics
Effect of genetic variability on drug toxicity and
efficacy
Pharmacokinetic variation and drug toxicity
Pharmacodynamic variation and drug efficacy
The common pharmacogenomics approach
Examples of pharmacogenomic markers
GENETIC VARIABILITY AND DRUG RESPONSE
Revenue opportunities in analysing genetic variability
Sequence variability
Genotyping by single nucleotide polymorphisms (SNPs)
Use of microarray chips and other methods for high
throughput sequencing
Expression variability
Use of microarray chips for analysing gene
expression
COMMERCIAL OPPORTUNITIES ARISING FROM GENETIC VARIABILITY
Pharmacogenomic diagnostics
Pharmacogenomic databases to guide drug development
Pharmacogenomic services
Applications of pharmacogenomics
1. Selection of existing drugs and treatments
2. Repositioning of drugs on the market
3. New indications for existing drugs
4. Selection for clinical trials
5. Resurrecting failed compounds
6. Preclinical toxicity screening
7. Discovering new drug targets
THE ROLE OF BIOINFORMATICS IN PHARMACOGENOMICS
CORPORATE COLLABORATIONS INVOLVING PHARMACOGENOMICS
CHAPTER 2 COMPANY PROFILES
Companies profiled
ABBOTT LABORATORIES
AFFYMETRIX INC
AMERICAN HOME PRODUCTS CORPORATION
Subsidiary Wyeth-Ayerst Laboratories
AMERSHAM PHARMACIA BIOTECH LTD
ASTRAZENECA PLC
AXYS PHARMACEUTICALS INC
Subsidiary Sequana Therapeutics Inc
BECTON, DICKINSON AND COMPANY
BIOGEN INC
CALIPER TECHNOLOGIES CORP
CELLTECH CHIROSCIENCE PLC
Subsidiary Rapigene Inc
COR THERAPEUTICS INC
CURAGEN CORP
DECODE GENETICS INC
DIADEXUS LLC
DIGITAL GENE TECHNOLOGIES INC
EURONA MEDICAL AB
EXONHIT THERAPEUTICS SA
GEMINI HOLDINGS PLC
Subsidiary: Gemini Research Ltd
Subsidiary: Gemini GeneData Ltd
GENAISSANCE PHARMACEUTICALS INC
GENE LOGIC INC
Subsidiary Oncormed Inc
GENEASIA INC
GENESCAPE INC
GENETRACE SYSTEMS INC
GENOME THERAPEUTICS CORP
GENOMICA CORP
GENSET SA
GENZYME CORPORATION
GLAXO WELLCOME PLC
Subsidiary Spectra Biomedical
HYSEQ INC
INCYTE PHARMACEUTICALS INC
Subsidiary Hexagen Inc
Joint venture diaDexus LLC
INFOGENE MEDIZINISCHE GENETIK GmbH
INTELLIGENT MEDICAL OBJECTS INC
INTERLEUKIN GENETICS INC
INTROGEN THERAPEUTICS INC
KIVA GENETICS INC
LYNX THERAPEUTICS INC
MASSTRACE INC
MERCK & Co
MILLENNIUM PHARMACEUTICALS INC
Subsidiary Millennium BioTherapeutics Inc.
Subsidiary Millennium Predictive
Medicine Inc. (MPMx)
MITOKOR
MOSAIC TECHNOLOGIES INC
NANOGEN INC
NOVA MOLECULAR DIAGNOSTICS INC
ONCOR INC
ORCHID BIOCOMPUTER INC
PANGEA SYSTEMS INC
PE CORPORATION
Divisions: PE Biosystems and PE GenScope
Subsidiary Molecular Informatics Inc
Joint venture Celera Genomics Corp
Subsidiary Celera Genomics Corporation
PHARMACEUTICAL PRODUCT DEVELOPMENT INC
Subsidiary PPD Discovery
Joint Venture: PPGx Inc.
PHARMACIA & UPJOHN INC
PHENOGENEX LLC
PPGx INC
PROTOGENE LABORATORIES
QUEST DIAGNOSTICS INC
Subsidiaries: Nichols Institute
Nichols Institute Diagnostics
QUINTILES TRANSNATIONAL CORP
RHONE-POULENC SA (AVENTIS)
Subsidiary Rhone-Poulenc Rorer Inc
ROCHE HOLDING LTD
Subsidiary Corange Ltd,
including Boehringer Mannheim GmbH
ROSETTA INPHARMATICS
SCHERING-PLOUGH CORPORATION
SEQUENOM INC
Subsidiary Sequenom GmbH
SIGNALGENE INC
SMITHKLINE BEECHAM PLC
Subsidiary SmithKline Beecham Corp
Joint venture diaDexus LLC
SNP CONSORTIUM LTD, The
STRUCTURAL BIOINFORMATICS INC
Subsidiary SBI-Advanced Technologies AS
SUGEN INC
SYNOMICS LTD
TERRAPIN TECHNOLOGIES INC
VARIAGENICS INC
Formerly KO Technology
Subsidiary Avitech Diagnostics Inc
Subsidiary Nova Molecular Diagnostics Inc
VECTAGEN
VISIBLE GENETICS INC
Subsidiary Applied Sciences Inc
Subsidiary ACT Gene SA
WARNER-LAMBERT COMPANY
Subsidiary: Parke Davis & Co Ltd
XENOMETRIX INC
CHAPTER 3 FINANCIAL AND MARKET ANALYSES
Pharmacogenomics market in 1998
Projected pharmacogenomics market in 2005
Major areas of pharmacogenomic activity
Cancer
Cardiovascular diseases
AIDS and other viral diseases
Central nervous system (CNS) conditions
Prevention of adverse drug reactions
Patent analysis
Pharmacogenomics company league tables
CHAPTER 4 TRENDS AND OPPORTUNITIES
Pharmacogenomics: first clinical application
of genomics
Resistance has given way to enthusiasm
Stratified markets may allow greater drug
penetration
Regulatory considerations favour pharmacogenomics
Pharmacogenomic tests are ethics-free
Doubts persist while vision outweighs data
Big pharma moves in through alliances
Pharmacogenomic companies focus on service provision
Short-term focus is on late-stage drug development
Next phase of pharmacogenomics will link it to drug
discovery
APPENDIX GLOSSARY OF TECHNICAL TERMS AND ABBREVIATIONS
LIST OF TABLES
TABLE 1.1 Companies specialising in sequence variation
TABLE 1.2 Companies developing gene expression analysis
systems
TABLE 1.3 Companies developing drug response diagnostics
and databases
TABLE 1.4 Companies developing databases/bioinformatics
relevant to pharmacogenomics
Table 1.5 Corporate alliances involving pharmacogenomics
July 1997 - August 1999
Table 3.1 Important applications of pharmacogenomics
Table 3.2 World Pharmaceutical Market by Region in 1998
Table 3.3 Sizes of Major Pharma Markets in 1998
Table 3.4 Pharmacogenomics market in 1998 and 2005
Table 3.5 Pharmacogenomics Company League Tables
- Total Revenues
Table 3.6 Pharmacogenomics Company League Tables
- Profitability
Table 3.7 Pharmacogenomics Company League Tables
- Total Assets
Table 3.8 Pharmacogenomics Company League Tables
- R&D Expenditure
|
